Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) just unveiled an update.
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its trastuzumab biosimilar, Dazublys®, intended for treating HER2-positive breast cancers. This endorsement marks an important step for Aurobindo Pharma in strengthening its biosimilars portfolio, with expectations for European Commission approval by July, furthering its commitment to launching at least ten biosimilars by 2030 to enhance cancer care and address unmet patient needs.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited, through its subsidiary CuraTeQ Biologics, is a global biopharmaceutical company based in Hyderabad, India, focusing on developing biosimilars for cancer and autoimmune diseases. The company aims to provide high-quality, cost-effective therapies with a pipeline of fourteen biosimilars targeting immunology and oncology segments.
YTD Price Performance: -6.94%
Average Trading Volume: 34,176
Current Market Cap: 730.4B INR
For an in-depth examination of AUROPHARMA stock, go to TipRanks’ Stock Analysis page.